SUNRAY-02

Lung Cancer

A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC.

Key Team Members

Principal Investigator

Scott Graupner, DO

Research Coordinator

Selena Lollar

Accepting Patients

Enrollment Started: October 31, 2025

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this research study is to learn more about olomorasib, a possible new investigational drug for the treatment of lung cancer. Investigational means that olomorasib is not approved by the United States Food and Drug Administration (FDA).